Navigation Links
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
Date:4/23/2009

LOS ANGELES (April 23, 2009) The Food and Drug Administration (FDA) gave its approval this week for Emmaus Medical, Inc. to begin a Phase 3 clinical trial of an experimental treatment for sickle cell disease. The patented experimental treatment was originally developed by investigators led by Yutaka Niihara, MD, MPH, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and is licensed to Emmaus Medical.

The patented drug treatment involves the oral administration of L-glutamine, which is the most common amino acid in the body. This is one of a very few experimental treatments for sickle cell disease to reach the Phase 3 clinical trial stage.

"News of this clinical trial should be of great interest to the millions of people around the world who suffer from painful crises caused by sickle cell disease," said Dr. Niihara. "Phase 3 clinical trials are large, randomized studies conducted at multiple sites to determine the safety and efficacy of a potential treatment. Phase 3 clinical trials are usually the last clinical trials conducted before FDA approval is obtained and the treatment can be made widely available to the patient population."

Sickle cell disease is an inherited disorder that causes red blood cells to become oxidized, sticky and sickle shaped instead of smooth, pliable and round. Sickle cell disease leads to anemia, organ damage, chronic and acute pain and a host of other problems.

"In our Phase 2 clinical trial, we observed an excellent safety profile and positive trends in reducing the number of crises and hospitalizations in sickle cell disease patients," said Dr. Niihara. "We look forward to initiating the Phase 3 clinical trial and remain committed to developing a treatment for sickle cell disease."


'/>"/>

Contact: Laura Mecoy
Lmecoy@issuesmanagement.com
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert  

Page: 1

Related medicine news :

1. Anticlotting drug found to be safe in sickle cell patients
2. New Kind of Stem Cells Reverse Sickle Cell Anemia
3. Children with sickle cell disease, silent strokes show some relief with blood transfusions
4. Sickle Cell Disease Pain Can Occur Daily and Is Much More Severe Than Previously Thought
5. Sickle Cell Patients in More Pain Than Thought
6. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
7. For children with sickle cell disease, lung disease is part of the package
8. Lung Trouble Associated With Sickle Cell in Kids
9. Researchers Develop Stem Line With Sickle Cell Mutation
10. Effective treatment for sickle cell underused by doctors
11. Sickle Cell Drug Underused by Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
(Date:5/27/2016)... ... ... Southland Log Homes , designer and manufacturer of America’s Favorite Log ... be found on its website at SouthlandLogHomes.com. , The designs of the wood ... craftsmanship of timber post and beam construction. The result is a barn that ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... factors of a stroke, which we as a society can control and change. , ... stroke occurs nearly every 40 seconds within the United States. Plus, with an estimated ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in the health ... of leaders in the nursing and health care industry. It also provides insight to ... Christian University. , As the nursing industry is coming out of one of ...
(Date:5/26/2016)... , ... May 26, 2016 , ... W.S. Badger ... has been honored with a 2016 When Work Works Award for its use of ... of the national When Work Works project administered by the Families and Work Institute ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... On Memorial ... and women who lost their lives in military battle for the country. The ... in 2015 to provide more programs that empower independence for disabled military veterans, as ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... NEW YORK , May 25, 2016  According ... devices reached $381 billion in 2015.  Though these ... still plenty of opportunity for success for companies ... end, in search of new growth prospects medical ... revenue on research and development (R&D) than do ...
(Date:5/25/2016)... May 25, 2016 As illustrated ... earlier this month, the numbers and momentum of cannabis ... climb into the billions, more research and development push ... Edition State of Legal Marijuana Markets Report  from from ... firm, much of the increase in sector is attributed ...
Breaking Medicine Technology: